Providing Targeted Cancer Diagnostics
-
A new division providing centralized laboratory testing, supporting Clinical Trials, Pharma and Biotech activities
-
Genetically defined human genomic reference standards (gDNA & FFPE)
-
Validated Image Analysis for accurate biomarker quantification.
-
Complete Digital Pathology for remote Case Review, Teaching & Research Pathology
-
Now performing Lymphoma, HER2 FISH/DDISH, ALK NSCLC & Bladder Cancer FISH
-
Specialist Breast & Gastric HER2 IHC testing services now available
-
Providing accredited IHC, ISH, Molecular & Digital Pathology services throughout the UK and overseas
-
Cutting edge research in Next Generation Sequencing for personalised medicine applications
-
Highly Sensitive Mutation Analysis Service for EGFR, KRAS & BRAF
Latest News
15/05/12 UCL-AD Attends Parliamentary Briefing on Targeted Cancer Diagnostics & Personalised Medicine
Representatives from UCL-AD/London Cancer & BCUK attend parliamentary briefing to discuss the importance of targeted testing and personalised medicine, with a specific focus on colorectal cancer, KRAS testing and Cetuximab.
15/05/12 New Genetic Reference Standards available from HorizonDx via UCL-AD
Genetically characterized X-MAN reference standards available to support discovery, development and routine molecular testing. X-MAN reference standards are genetically defined standards enabling accurate technology benchmarking for pharmaceutical and diagnostic development. Read more...
26/04/12 New FDA Approved ALK Gene Rearrangement Test Available for NSCLC Patients
UCL-AD now performs the Abbott Molecular ALK Break-apart FISH assay for determination of suitability for NSCLC patients for a treatment regimen including Crizotinib. Read more...
26/04/12 Fully Funded KRAS Testing for ALL NHS Colorectal Cancer Patients
UCL-AD now offers a Merck Serono funded KRAS testing service for ALL NHS patients diagnosed with colorectal cancer. Identifying patients with wild-type KRAS mCRC, who may benefit from a tretament regimen including Erbitux (Cetuximab). Read more...
26/04/12 UCL-AD Supports use of new Roche HER2 Teaching Resource
Roche unveil new HER2 teaching resource. The 'HER2testing' web resource supports interpretation of HER2 testing in breast and gastric cancer in all areas including IHC, CISH, FISH and DDISH and provides a valuable resource for scientists and pathologists. Read more...
26/04/12 UCL-AD Adopts Roche Companion Diagnostics Testing Platform
UCL-AD has chosen to adopt Roche Pathway HER2 (4B5) and Inform HER2 DDISH on the Benchmark ULTRA automated staining system for use in breast and gastric cancer HER2 testing applications.